Gilead Sciences
Latest Gilead Sciences News
-
FDA Rejects 2 HIV Drugs From Gilead Sciences
Gilead Sciences Inc . said Monday that the Food and Drug documentations and quality testing at Gilead Sciences ' facilities. The company said in a are already approved as ingredients in Gilead 's four-in-one HIV pill Stribild
-
FDA Rejects 2 HIV Drugs From Gilead Sciences
Gilead Sciences Inc . says that the Food and Drug Administration rejected two marketing regulators have found problems with documentations and quality testing at Gilead Sciences ' facilities. The company said in a release it is working to address
-
Truvada Gets FDA Nod for HIV Preventionthe fight against AIDS. The drug, Truvada, is actually a combination of two medicines and is manufactured by Gilead Sciences , Inc . of Foster City, Calif. While Truvada has been approved since 2004 as a treatment for those already infected
-
Truvada for HIV Prevention: Pros, Cons of Popping a Pill
support and close follow-up, it can clearly make a difference in people's lives." FDA approval would allow Gilead Sciences , the maker of Truvada, to market the drug for HIV prevention. It could convince insurers to cover the cost, estimated
-
Vaginal Gel Intended to Cut AIDS Works for Herpes Too
from researchers at the National Institutes of Health, Gilead Sciences Inc . and universities in Belgium and Italy. The New York Times Public Health, told ABCNews.com. Tenovir, made by Gilead — which participated in the microbicide study — is used in
-
Stock options swell CEO pay
stock promised earlier that was worth $22 million. Value of Ryan's 2010 compensation: $65.7 million. • Gilead Sciences CEO John Martin gained $35.8 million. That's on top of compensation valued at $14.2 million. His 2010 total
News
-
CEO pay soars while workers' pay stalls
CEOs are starting to cash in options they received in years when stock values were decimated. John Martin, CEO of Gilead Sciences , cashed in $35.8 million in options previously awarded, outstripping the $14.2 million he received in total pay
-
Some investors have bull market blues
Arts up 16%. Among biotechs, Gilead Sciences is down 12% and Cephalon is down company, future products are key. Gilead is best known for its lineup of the stock a "buy," as he thinks Gilead will find new products. Similarly
-
Investors look for stocks that could gain from swine flu
GlaxoSmithKline's gsk Relenza and Gilead Sciences gild ' co-developed Tamiflu are two Jason Kolbert of ThinkEquity. Gilead gets a roughly 20% royalty from which makes and sells the product. Gilead stands to benefit if the regular
-
Drug Offers Hope Against Tough-to-Treat Hypertension
marketing approval, said Nathan Kaiser, a spokesman for Gilead Sciences , the company that is developing the drug. "A larger Hospital, New York City; Nathan Kaiser, spokesman, Gilead Sciences , Foster City, Calif.; Michael A. Weber, M
-
HIV 'Atlas' Shows Virus Targeting Minorities
detection is the key." The report, put together by the National Minority Quality Forum with support from drug company Gilead Sciences , is the first ground-level look at the HIV/AIDS epidemic in the United States. "We wanted to make sure that
-
Glaxo, Novavax, other drug stocks leap due to swine flu
flu outbreak will reinvigorate stockpiling, says Jason Kantor, biotech analyst for RBC Capital Markets. He covers Gilead Sciences , which developed Tamiflu and gets royalties from Roche. The outbreak "raises the awareness that these threats still
-
Swine flu worries put a damper on stocks
Some pharmaceutical stocks, however, climbed. GlaxoSmithKline gained 7.6%, rising $2.22 to $31.56, and Gilead Sciences rose 3.8%, climbing $1.73 to $47.53. The two companies make flu treatments. Although the swine flu distracted
Videos
-
Who Should You Work For?I go back and take a look at the rest of this year's top five head coach in the number one position. And we had Gilead Sciences . Why was why did they make that number two position. is really interest in company that kind of spotted an opportunity
top five head coach in the number one position. And we had Gilead Sciences . Why was why did they make that number two position. -- is -- really interest in company that kind of spotted an
